SPECTRAL MEDICAL INC (EDT.CA) Fundamental Analysis & Valuation
TSX:EDT • CA8475771033
Current stock price
1.4 CAD
+0.03 (+2.19%)
Last:
This EDT.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. EDT.CA Profitability Analysis
1.1 Basic Checks
- EDT had negative earnings in the past year.
- In the past year EDT has reported a negative cash flow from operations.
- EDT had negative earnings in each of the past 5 years.
- EDT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -781.82%, EDT is not doing good in the industry: 78.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -781.82% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-457.3%
ROA(5y)-308.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 54.30%, EDT belongs to the top of the industry, outperforming 91.30% of the companies in the same industry.
- In the last couple of years the Gross Margin of EDT has declined.
- EDT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y-4.95%
2. EDT.CA Health Analysis
2.1 Basic Checks
- EDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- EDT has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for EDT has been increased compared to 5 years ago.
- The debt/assets ratio for EDT is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -55.07, we must say that EDT is in the distress zone and has some risk of bankruptcy.
- EDT's Altman-Z score of -55.07 is on the low side compared to the rest of the industry. EDT is outperformed by 65.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -55.07 |
ROIC/WACCN/A
WACC8.79%
2.3 Liquidity
- EDT has a Current Ratio of 0.08. This is a bad value and indicates that EDT is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of EDT (0.08) is worse than 65.22% of its industry peers.
- A Quick Ratio of 0.07 indicates that EDT may have some problems paying its short term obligations.
- The Quick ratio of EDT (0.07) is worse than 60.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.07 |
3. EDT.CA Growth Analysis
3.1 Past
- EDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -202.55%.
- The Revenue has been growing slightly by 6.82% in the past year.
- EDT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.06% yearly.
EPS 1Y (TTM)-202.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-187.39%
Revenue 1Y (TTM)6.82%
Revenue growth 3Y13.5%
Revenue growth 5Y3.06%
Sales Q2Q%-40.78%
3.2 Future
- The Earnings Per Share is expected to grow by 32.76% on average over the next years. This is a very strong growth
- EDT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 142.59% yearly.
EPS Next Y73.87%
EPS Next 2Y41.42%
EPS Next 3Y34.94%
EPS Next 5Y32.76%
Revenue Next Year91.66%
Revenue Next 2Y129.92%
Revenue Next 3Y163.87%
Revenue Next 5Y142.59%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. EDT.CA Valuation Analysis
4.1 Price/Earnings Ratio
- EDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EDT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- EDT's earnings are expected to grow with 34.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y34.94%
5. EDT.CA Dividend Analysis
5.1 Amount
- No dividends for EDT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EDT.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:EDT (4/24/2026, 7:00:00 PM)
1.4
+0.03 (+2.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2026-03-26/bmo
Earnings (Next)05-08 2026-05-08
Inst Owners0.1%
Inst Owner ChangeN/A
Ins Owners1.68%
Ins Owner ChangeN/A
Market Cap410.79M
Revenue(TTM)2.44M
Net Income(TTM)-47.69M
Analysts83.33
Price Target3.21 (129.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.61%
PT rev (3m)1.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-33.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 168.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.15
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.24
TBVpS-0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -781.82% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.3% | ||
| FCFM | N/A |
ROA(3y)-457.3%
ROA(5y)-308.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.55%
GM growth 5Y-4.95%
F-Score2
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 78% | ||
| Cap/Sales | 7.99% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.07 | ||
| Altman-Z | -55.07 |
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)57.87%
Cap/Depr(5y)68.87%
Cap/Sales(3y)6.91%
Cap/Sales(5y)9.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-202.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-187.39%
EPS Next Y73.87%
EPS Next 2Y41.42%
EPS Next 3Y34.94%
EPS Next 5Y32.76%
Revenue 1Y (TTM)6.82%
Revenue growth 3Y13.5%
Revenue growth 5Y3.06%
Sales Q2Q%-40.78%
Revenue Next Year91.66%
Revenue Next 2Y129.92%
Revenue Next 3Y163.87%
Revenue Next 5Y142.59%
EBIT growth 1Y48.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.01%
OCF growth 3YN/A
OCF growth 5YN/A
SPECTRAL MEDICAL INC / EDT.CA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SPECTRAL MEDICAL INC (EDT.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to EDT.CA.
Can you provide the valuation status for SPECTRAL MEDICAL INC?
ChartMill assigns a valuation rating of 1 / 10 to SPECTRAL MEDICAL INC (EDT.CA). This can be considered as Overvalued.
How profitable is SPECTRAL MEDICAL INC (EDT.CA) stock?
SPECTRAL MEDICAL INC (EDT.CA) has a profitability rating of 1 / 10.
What is the financial health of SPECTRAL MEDICAL INC (EDT.CA) stock?
The financial health rating of SPECTRAL MEDICAL INC (EDT.CA) is 0 / 10.